Episode Details

On the latest TDR Cannabis in Five presented by Flowhub, host Shadd Dales breaks down newly released details around a federal CBD pilot program tied to Medicare patients — and why the timing is raising questions across the cannabis industry.According to reporting from Marijuana Moment, the program will allow select Medicare patients to receive up to $500 annually in hemp-derived cannabinoid products, including orally administered formats like tinctures, capsules, and edibles. These products can include limited amounts of THC and must comply with state laws.What stands out is how the program is structured. Rather than direct federal reimbursement, it’s being implemented through ACO-style healthcare groups that are incentivized to reduce overall patient costs. That means cannabinoid treatments are only being used when providers believe they can improve outcomes and reduce healthcare spending.At the same time, cannabis remains federally classified as a Schedule I substance.This episode looks at that disconnect — and what it could signal. Whether this is an early-stage workaround or part of a broader shift in federal policy, it represents one of the first real examples of cannabinoids being introduced into a federally connected healthcare system.For investors and operators, the takeaway is straightforward: this is still a limited pilot, but it may point to where things are heading next.Want to see more Cannabis Reform videos?🎬    • Does Cannabis Rescheduling Actually Unlock...  🎬    • Texas Hemp Ban Creates Winners And Losers ...  🎬    • Texas Hemp Market Faces Major Regulatory C...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn: